Swedish biotech firm AAX gets new CEO

Biotech company AAX Biotech, specialising in innovative, patentable technologies for improving antibody-based medicines, has appointed Maria Lisa Knudsen as CEO.

The appointment is expected to contribute to the company’s growth and the development of its pioneering technologies.

AAX Biotech is a Swedish startup biotech company aiming to solve unmet needs in developing next-generation antibody therapeutics.

The company’s two patentable technologies, Seqitope and Opti-mAb, improve the performance and develop-ability of antibody-based therapeutics and offer a unique solution in a rapidly growing market.

Knudsen has a broad international experience in research and business development. Having obtained a PhD in Infection Biology from the prestigious Karolinska Institutet, she conducted extensive research at renowned institutions in the United States and Singapore.

Subsequently, she made a transition to the role of business development director at Salipro Biotech AB in Sweden, where she was involved in out-licensing the company’s technology platform for drug discovery as well as establishing an internal pipeline.

“We are thrilled to have Maria join the team as we strengthen our IP portfolio and build partnerships with biotech and pharma companies. Maria’s combined experience in antibody research and business development will be instrumental for advancing AAX Biotech’s cutting-edge technologies for antibody therapeutics,” says Daniel Johansson, co-founder and chief scientific officer of AAX Biotech.

Knudsen said: “I am honoured to take the role of leading AAX Biotech. It is an exciting new company with unique technologies that have the potential to significantly accelerate the development of next-generation antibody drugs that address unmet medical needs, improving therapeutics and patient lives.

“I look forward to working with the innovative team at AAX Biotech and fulfilling our vision of becoming a distinguished and highly competitive partner serving the global biopharmaceutical industry in the next couple of years”.

AAX Biotech aims to become a key player with a game-changing potential for next-generation antibody therapies such as bispecific antibodies and CAR-T cell treatments in the field of cancer care.

The company is dedicated to advancing this promising area through cutting-edge technologies, with a focus on amplifying the development and efficacy of these innovative treatments.